At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 60 enrolled

Drug / intervention

epratuzumab +1 morebiological

Likely dose

epratuzumab 360mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00553501

NCT00553501Phase 2Completed

Compare CT.gov

A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Alliance for Clinical Trials in Oncology·interventional·Posted Nov 5, 2007·Updated Jul 6, 2016

In Brief

A Phase 2 clinical trial evaluating epratuzumab and rituximab for Lymphoma. Completed, enrolled 60 participants across 43 sites.

Detailed Summary

RATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving epratuzumab and rituximab together may be more effective in treating follicular non-Hodgkin lymphoma. PURPOSE: This phase II trial is studying how well giving epratuzumab together with rituximab works in treating patients with previously untreated follicular non-Hodgkin lymphoma.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLymphoma

CountriesUnited States

CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished

20082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedNov 2007

Enrollment StartMar 2008

Primary CompletionJul 2010

Study CompletionJul 2014

TodayJul 2026

First PostedNov 5, 2007

Enrollment StartMar 1, 2008

Primary CompletionJul 1, 2010

Study CompletionJul 1, 2014

TodayJul 2, 2026

Enrollment to primary: 2.3 yearsPosted 18.7 years ago

Interventions

epratuzumabbiological

Days 1, 8, 15, 22 and weeks 12, 20, 28, \& 36: 360mg/sq m IV

rituximabbiological

Day 3, 8, 15, 22 and weeks 12, 20, 28, \& 36: 375mg/sq m IV